```markdown
---
nda: 214520
applicant: CorMedix Inc.
contact_person:
  name: Phoebe Mounts, PhD, Esq.
  title: Executive Vice President and General Counsel
  address: 5825 Bellanca Drive, Elkridge, MD 21075
application_type: NDA
submission_date: 2020-06-30
proprietary_name: Defencath (not accepted)
active_ingredients:
  - Taurolidine 67.5 mg/5 mL (13.5 mg/mL)
  - Heparin 5,000 USP Units/5 mL (1,000 Units/mL)
review_status: Complete Response Letter (Not Approved)
response_required_within: 1 year
inspected_facility:
  name: Rovi Pharma Industrial Services S.A.
  FEI: 3016688535
contact_fda:
  name: Kristine Park, PhD, RAC
  title: Senior Regulatory Health Project Manager
  phone: (301) 796-0471
signatory:
  name: John Farley, MD, MPH
  title: Director, Office of Infectious Diseases, Office of New Drugs, CDER
---

## Critical Data

| Field                       | Value                                                                 |
|----------------------------|-----------------------------------------------------------------------|
| NDA Number                 | 214520                                                                |
| Applicant                  | CorMedix Inc.                                                         |
| Contact Person             | Phoebe Mounts, PhD, Esq.                                              |
| Title                      | EVP and General Counsel                                               |
| Address                    | 5825 Bellanca Drive, Elkridge, MD 21075                               |
| Proprietary Name (Proposed)| Defencath (unacceptable)                                              |
| Active Ingredients         | Taurolidine 67.5 mg/5 mL, Heparin 5,000 USP Units/5 mL                |
| Review Status              | Complete Response Letter (Not Approved)                              |
| Facility Inspected         | Rovi Pharma Industrial Services S.A. (FEI 3016688535)                |
| Required Resubmission Time | Within 1 year per 21 CFR 314.110                                     |
| FDA Contact                | Kristine Park, PhD, RAC — (301) 796-0471                              |
| FDA Signatory              | John Farley, MD, MPH — Director, Office of Infectious Diseases, CDER |

---

# NDA 214520 — Complete Response Letter  

**Applicant:** CorMedix Inc.  
**Attention:** Phoebe Mounts, PhD, Esq.  
Executive Vice President and General Counsel  
5825 Bellanca Drive  
Elkridge, MD 21075

---

## Background

Please refer to your new drug application (NDA) dated June 30, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for:

- Taurolidine 67.5 mg/5 mL (13.5 mg/mL)  
- Heparin 5,000 USP Units/5 mL (1,000 Units/mL)  

Catheter lock solution (proposed proprietary name: Defencath).

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. Our reasons and recommendations are provided below.

---

## Product Quality / Facility Inspections

### (1) Facility

During an inspection of Rovi Pharma Industrial Services S.A. (FEI 3016688535), FDA found deficiencies. These must be satisfactorily resolved prior to approval.

### (2) Additional Facility Information

- Facilities listed in the DMF for Heparin Sodium were not listed in your application (Form FDA 356h and/or Section 3.2.S.2.1).
- Contact the DMF holder to resolve discrepancies.
- Add the supporting facilities to Form FDA 356h and Section 3.2.S.2.1.
- Letters of Authorization should specify which facilities support the application.

---

## Prescribing Information

### (3) General Requirements

Your proposed Prescribing Information (PI) must conform to content and format regulations per 21 CFR 201.56(a), (d), and 201.57. Refer to these resources:

- [PLR Requirements for Prescribing Information](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084159.htm)
- [Pregnancy and Lactation Labeling Final Rule](http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm)
- [Structured Product Labeling (SPL) Format](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)

**Resources and Tools:**

- Final Rules (PLR and PLLR)
- Guidance documents
- SRPI checklist
- EPC text phrases
- Sample labeling format

### Submission Requirements

- Submit a marked-up and clean Word version of the PI
- Highlight all changes
- Include annotations supporting changes
- Submit content of labeling in SPL format per 21 CFR 314.50(l)(1)(i)

---

## Carton and Container Labeling

### (4) Requirements

- Replace placeholder NDCs (NDC XXXXX-XXX-XX) with actual NDCs.
- Align labeling with proposed PI (Section 16).
- Submit updated draft carton and container labeling after receiving specific FDA communication.

---

## Proprietary Name

### (5) Name Determination

- The proposed name "Defencath" is unacceptable due to potential confusion with another product in review.
- Ultimate acceptability depends on which application is approved first.
- If keeping "Defencath" as preferred, indicate in cover letter.
- Alternate name proposed on March 3, 2022: submit a new request for review.

---

## Safety Update

When responding to deficiencies, include a safety update per 21 CFR 314.50(d)(5)(vi)(b), covering all nonclinical and clinical trial data.

### Requirements:

1. Describe significant changes in safety profile.
2. For AEs:
   - Present new data using original format.
   - Combine new and original safety tabulations.
   - Compare AE frequencies.
   - Provide tables for other indications separately.
3. Retabulate trial discontinuations:
   - Include dropouts from new trials
   - Highlight trends or patterns
4. Provide:
   - Case report forms and narratives for deaths and serious AEs
   - Narratives for all SAEs
5. Describe any substantial change in incidence of common, less serious AEs.
6. Provide updated exposure data:
   - Number of subjects
   - Person-time
7. Provide a summary of global safety experience.
8. Provide English translations of current approved foreign labeling.

---

## Additional Notes

- If determined necessary, an inspection will be arranged when safe travel resumes (due to COVID-19).
- Refer to [FDA COVID-19 Guidance](https://www.fda.gov/emergency-preparedness-and-/coronavirus-disease-2019-covid-19/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders)

---

## Other Instructions

- You are required to resubmit or take other action within 1 year of this letter per 21 CFR 314.110.
- If no response, FDA may consider it a request to withdraw under 21 CFR 314.65.
- Extensions may be requested.

### Resubmission Requirements:

- Clearly marked “RESUBMISSION” in large, bold type at the beginning of the cover letter
- State it is a complete response to the deficiencies listed in this letter
- Partial responses will not start a new review cycle

---

## Meetings

You may request a meeting or teleconference with the FDA to discuss next steps. Submit your request in accordance with the draft guidance:

- *Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products*

---

## Contact

If you have any questions:

Kristine Park, PhD, RAC  
Senior Regulatory Health Project Manager  
Phone: (301) 796-0471

---

## Signature

John Farley, MD, MPH  
Director  
Office of Infectious Diseases  
Office of New Drugs  
Center for Drug Evaluation and Research

---

## Enclosure(s):

- Labeling  
  - Prescribing Information  
    **Note:** 9 pages of draft labeling withheld in full as (b)(4)
```